BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36345721)

  • 21. p53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers.
    Bond CE; Umapathy A; Ramsnes I; Greco SA; Zhen Zhao Z; Mallitt KA; Buttenshaw RL; Montgomery GW; Leggett BA; Whitehall VL
    Int J Cancer; 2012 Apr; 130(7):1567-76. PubMed ID: 21557216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.
    Mehta RS; Song M; Nishihara R; Drew DA; Wu K; Qian ZR; Fung TT; Hamada T; Masugi Y; da Silva A; Shi Y; Li W; Gu M; Willett WC; Fuchs CS; Giovannucci EL; Ogino S; Chan AT
    Gastroenterology; 2017 Jun; 152(8):1944-1953.e1. PubMed ID: 28249812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.
    Shima K; Morikawa T; Yamauchi M; Kuchiba A; Imamura Y; Liao X; Meyerhardt JA; Fuchs CS; Ogino S
    PLoS One; 2011; 6(9):e25062. PubMed ID: 21949851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer.
    Kohonen-Corish MR; Tseung J; Chan C; Currey N; Dent OF; Clarke S; Bokey L; Chapuis PH
    Int J Cancer; 2014 Jun; 134(12):2820-8. PubMed ID: 24259266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer.
    Liu J; Tang L; Yi J; Li G; Lu Y; Xu Y; Zhao S; Mao R; Li X; Ren L; Wang K
    BMC Gastroenterol; 2019 Nov; 19(1):173. PubMed ID: 31690257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.
    Murcia O; Juárez M; Hernández-Illán E; Egoavil C; Giner-Calabuig M; Rodríguez-Soler M; Jover R
    World J Gastroenterol; 2016 Apr; 22(13):3516-30. PubMed ID: 27053844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.
    Nosho K; Irahara N; Shima K; Kure S; Kirkner GJ; Schernhammer ES; Hazra A; Hunter DJ; Quackenbush J; Spiegelman D; Giovannucci EL; Fuchs CS; Ogino S
    PLoS One; 2008; 3(11):e3698. PubMed ID: 19002263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.
    Liao X; Morikawa T; Lochhead P; Imamura Y; Kuchiba A; Yamauchi M; Nosho K; Qian ZR; Nishihara R; Meyerhardt JA; Fuchs CS; Ogino S
    Clin Cancer Res; 2012 Apr; 18(8):2257-68. PubMed ID: 22357840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
    Kim JH; Bae JM; Cho NY; Kang GH
    Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.
    Loh M; Liem N; Vaithilingam A; Lim PL; Sapari NS; Elahi E; Mok ZY; Cheng CL; Yan B; Pang B; Salto-Tellez M; Yong WP; Iacopetta B; Soong R
    BMC Gastroenterol; 2014 Mar; 14():55. PubMed ID: 24674026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea.
    Kim KM; Lee EJ; Ha S; Kang SY; Jang KT; Park CK; Kim JY; Kim YH; Chang DK; Odze RD
    Am J Surg Pathol; 2011 Sep; 35(9):1274-86. PubMed ID: 21836485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.
    Bae JM; Kim JH; Cho NY; Kim TY; Kang GH
    Br J Cancer; 2013 Aug; 109(4):1004-12. PubMed ID: 23900220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer.
    Renaud F; Vincent A; Mariette C; Crépin M; Stechly L; Truant S; Copin MC; Porchet N; Leteurtre E; Van Seuningen I; Buisine MP
    Int J Cancer; 2015 Jun; 136(12):2811-21. PubMed ID: 25403854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microsatellite instability, MLH1 promoter methylation, and BRAF mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel.
    Vilkin A; Niv Y; Nagasaka T; Morgenstern S; Levi Z; Fireman Z; Fuerst F; Goel A; Boland CR
    Cancer; 2009 Feb; 115(4):760-9. PubMed ID: 19127559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer.
    Domingo E; Ramamoorthy R; Oukrif D; Rosmarin D; Presz M; Wang H; Pulker H; Lockstone H; Hveem T; Cranston T; Danielsen H; Novelli M; Davidson B; Xu ZZ; Molloy P; Johnstone E; Holmes C; Midgley R; Kerr D; Sieber O; Tomlinson I
    J Pathol; 2013 Feb; 229(3):441-8. PubMed ID: 23165447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer.
    Chen KH; Lin YL; Liau JY; Tsai JH; Tseng LH; Lin LI; Liang JT; Lin BR; Hung JS; Chang YL; Yeh KH; Cheng AL
    Med Oncol; 2016 May; 33(5):39. PubMed ID: 27034263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.